Question-and-Answer Session
Operator
Thank you. Our first question comes from Frank Pinkerton of Bank of America. Sir, your line is open. Mr. Pinkerton.
Frank Pinkerton - Banc of America Securities
Thanks. Sorry. Can you hear me?
David Pyott
Yes.
Just some quick questions on BOTOX please. Can you provide the contribution that US headaches sales would provide to BOTOX. Can you just go over quickly the inclusion criteria for the headache study that will report out later this summer?
And then finally, can you compare those inclusion criteria potentially to some of the higher subscribers or higher users of BOTOX, than that, you know, have historically used it there on the headache side. Thank you.
David Pyott
Well let me answer the question regarding current sales of US headache. Regarding all of our areas, we attempt to answer that question by survey and we strongly believe that BOTOX headache sales in the US today are in fact even smaller than those of BOTOX for hyperhidrosis. So you can see it's a very small part of our overall franchise in the United States. In terms of the clinical questions, I'll turn it over to Scott.
Scott Whitcup
In terms of the clinical trials design, what we've disclosed. The trials involve patients with chronic daily headaches, so these are patients who have headaches. About half of the month, most of those headaches tend to be migraine-type headaches.
You'd think that this is the severe end of the spectrum but there are actually, you know in the 10 to 15 million patients in the US range with this type of headache. So we think that for the people who are out there using BOTOX for headache is a big part of the market that they're currently treating. In terms of inclusion and exclusion criteria, the other thing that we've said, if you look at the Phase II study, they are very heterogeneous.
People were allowed to take escape medications, prophylactic medications and that confounded the trial. In the Phase III trials we presented patients coming in on prophylactics and very carefully monitored escape medications as part of the protocol. We think that optimizes our chance for success of the trial.
Frank Pinkerton - Banc of America Securities
Thank you.
Operator:
Our next question comes from David Buck with Buckingham Research Group. Your line is open.
David Buck – Buckingham Research Group
Thanks. For the first question on BOTOX is just the cash paid business. David can you give sense of what you think may have changed in the last three months in terms of I guess the resistance of your products to the consumer slow-down and can you give a sense of why you're actually comfortable keeping the guidance at 12.6, 16% plus growth for this year, with Europe potentially slowing down later in the year. Thanks.
- To read the full transcript on Seeking Alpha, click here »
